Skip to main content
OpenTrials

Clinical trial condition

Urologic Diseases

Explore clinical trials studying Urologic Diseases. Study availability and eligibility vary by location and protocol.

13,603 public trials 2,148 recruiting studies
Refine in advanced search Browse all conditions

Urologic Diseases trial results

Active, Not Recruiting

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) Duarte, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro Los Angeles, California, United States
  • UCSF Medical Center at Mission Bay ( Site 0108) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) New Haven, Connecticut, United States
View all 63 locations
View Trial Details
Active, Not Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney Diseases, +5 more
Locations
  • Mount Sinai Hosp Med School New York, United States
  • Novartis Investigative Site Paris, France
  • Novartis Investigative Site Vandœuvre-lès-Nancy, France
  • Novartis Investigative Site Essen, Germany
View Trial Details
Active, Not Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591

Conditions
Carcinoma, Carcinoma in Situ, Female Urogenital Diseases, +15 more
Locations
  • Urology Centers Alabama Homewood, Alabama, United States
  • BCG Oncology Phoenix, Arizona, United States
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • Arizona Institute of Urology Tucson, Arizona, United States
View all 86 locations
View Trial Details
Active, Not Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

NCT03213652

Conditions
Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 126 locations
View Trial Details
Active, Not Recruiting

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT06544330

Conditions
Autoimmune Diseases, Connective Tissue Diseases, Female Urogenital Diseases, +15 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Feinstein Institutes for Medical Research Manhasset, New York, United States
  • Columbia University Irving Medical Center New York, United States
View Trial Details

Related conditions